Following a year in which revenue from partnerships rose and new deals were secured, Evotec SE has forecast a higher turnover for 2022 and more aggressive spending on R&D. Werner Lanthaler, the chief executive, gave an upbeat financial forecast in a briefing for analysts on 12 April, emphasising the resilience of the company’s core service business where it provides drug discovery support to third parties across a wide range of disease areas. In 2021, the company was involved in 842 alliances and recorded a repeat business of 91%.
